Want to see HK:2511 full AI Analyst Report?
Total Valuation
Hightide Therapeutics Inc has a market cap or net worth of HK$2.08B. The enterprise value is HK$1.17B.
Market CapHK$2.08B
Enterprise ValueHK$1.17B
Share Statistics
Hightide Therapeutics Inc has 670,035,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding670,035,640
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Hightide Therapeutics Inc’s return on equity (ROE) is -0.80 and return on invested capital (ROIC) is -45.45%.
Return on Equity (ROE)-0.80
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-45.45%
Return on Capital Employed (ROCE)-0.49
Revenue Per Employee0.00
Profits Per Employee-4.55M
Employee Count51
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Hightide Therapeutics Inc is ―. Hightide Therapeutics Inc’s PEG ratio is 0.13.
PE Ratio―
PS Ratio0.00
PB Ratio4.14
Price to FCF-7.61
Price to Operating Cash Flow-9.65
PEG Ratio0.13
Income Statement
In the last 12 months, Hightide Therapeutics Inc had revenue of 0.00 and earned -244.97M in profits. Earnings per share was -0.51.
Revenue0.00
Gross Profit0.00
Operating Income-223.57M
Pretax Income-231.88M
Net Income-244.97M
EBITDA-217.31M
Earnings Per Share (EPS)-0.51
Cash Flow
In the last 12 months, operating cash flow was -154.05M and capital expenditures -291.04K, giving a free cash flow of -154.34M billion.
Operating Cash Flow-154.05M
Free Cash Flow-154.34M
Free Cash Flow per Share-0.23
Dividends & Yields
Hightide Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.09
52-Week Price Change-1.30%
50-Day Moving Average3.33
200-Day Moving Average3.08
Relative Strength Index (RSI)51.18
Average Volume (3m)539.26K
Important Dates
Hightide Therapeutics Inc upcoming earnings date is Mar 26, 2027, Before Open (Confirmed).
Last Earnings DateAug 31, 2026
Next Earnings DateMar 26, 2027
Ex-Dividend Date―
Financial Position
Hightide Therapeutics Inc as a current ratio of 5.41, with Debt / Equity ratio of 92.66%
Current Ratio5.41
Quick Ratio5.41
Debt to Market Cap0.09
Net Debt to EBITDA0.49
Interest Coverage Ratio-97.09
Taxes
In the past 12 months, Hightide Therapeutics Inc has paid 219.00K in taxes.
Income Tax219.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Hightide Therapeutics Inc EV to EBITDA ratio is -5.36, with an EV/FCF ratio of -6.98.
EV to Sales0.00
EV to EBITDA-5.36
EV to Free Cash Flow-6.98
EV to Operating Cash Flow-6.98
Balance Sheet
Hightide Therapeutics Inc has HK$326.36M in cash and marketable securities with HK$154.73M in debt, giving a net cash position of HK$171.63M billion.
Cash & Marketable SecuritiesHK$326.36M
Total DebtHK$154.73M
Net CashHK$171.63M
Net Cash Per ShareHK$0.26
Tangible Book Value Per ShareHK$0.76
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Hightide Therapeutics Inc is HK$5.60, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$5.60
Price Target Upside83.61% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast14.40%